Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore rare renal disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Important Safety Information | Patient Site
Prescribing Information
Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] logo

Indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. Esperoct® is not indicated for the treatment of von Willebrand disease.

Prescribing Information
Important Safety Information | Patient Site

Patients can be on the go with Esperoct®—a flexibility factor1‑5,a

You have the flexibility to store Esperoct® anywhere from 36 °F to 104 °F.1,a

See below for storage details

EHL = extended half-life.

aPrior to reconstitution, Esperoct® can be stored from 36 °F to 46 °F for up to 30 months, at room temperature up to 86 °F for up to 12 months, or up to 104 °F for up to 3 months.1 See Prescribing Information for complete product storage information.

Bradley has
hemophilia A
and uses
Esperoct®.

Bradley has
hemophilia A
and uses
Esperoct®.

Before reconstitution:

Esperoct® temperature storage data from 36 to 46 degrees for up to 30 months, from 86 degrees for up to 12 months, from 104 degrees for up to 3 months

After reconstitution: Use Esperoct® within 4 hours when stored up to 86 °F or within 24 hours when stored in the refrigerator.1

Hand holding an Esperoct® box

Esperoct® has the broadest storage temperature of ALL EHL products and compact packaging for easy storage.1-5

Ready when your patients are

Esperoct® is ready in 3 simple steps: Attach, Twist, and Mix. Your patients can infuse over 2 minutes.1

Please note: these are not the complete Esperoct® Instructions for Use. Please see the Instructions for Use provided with the Prescribing Information.

Esperoct® attach, twist, mix
Esperoct® multiple vials

5 vial sizes for personalized treatment

Individualize prophylactic dosing frequency1 for your patients based on bleeding episodes. Esperoct® is an extended half-life (EHL) rFVIII with multiple vial sizes to choose from.

One proven starting dose for adults & adolescents

One proven starting dose for children

Help your patients navigate coverage

Father and son smiling

NovoCare® offers cost savings and support programs for your eligible patients with bleeding disorders.

Order Esperoct® for your patients

Esperoct® package

Order Esperoct® by phone, through an authorized trading partner, or by contacting your local Novo Nordisk representative.

Selected Important Safety Information for Esperoct®

Contraindications

  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins

Warnings and Precautions

  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment

Indications and Usage

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes

  • Esperoct® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications

  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins

Warnings and Precautions

  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
  • Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct® or if the expected plasma Factor VIII activity levels are not attained

Adverse Reactions

  • The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions

Please click here for Esperoct® Prescribing Information.

References:
  1. Esperoct® [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; 2022.
  2. Eloctate® [package insert]. Bioverativ Therapeutics Inc.; 2023.
  3. Adynovate® [package insert]. Lexington, MA: Baxalta US Inc.; 2023.
  4. Jivi® [package insert]. Whippany, NJ: Bayer HealthCare LLC; 2018.
  5. Altuviiio™ [package insert]. Waltham, MA: Bioverativ Therapeutics Inc.; 2023